BB&T is the famous Corporate Investor, which was founded in 1872. The leading representative office of defined Corporate Investor is situated in the Winston Salem. The fund was located in North America if to be more exact in United States.
Among the most popular portfolio startups of the fund, we may highlight Kythera Biopharmaceuticals, CVRx, OvaScience. We can highlight the next thriving fund investment areas, such as Life Science, Biotechnology. The fund has no exact preference in some founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
Besides them, we counted 25 critical employees of this fund in our database.
The typical case for the fund is to invest in rounds with 7-8 participants. Despite the BB&T, startups are often financed by Versant Ventures, The New York Times, Prospect Venture Partners. The meaningful sponsors for the fund in investment in the same round are Versant Ventures, Prospect Venture Partners, New Enterprise Associates. In the next rounds fund is usually obtained by Ysios Capital, Versant Ventures, Sterling Capital Management.
The important activity for fund was in 2008. Despite it in 2019 the fund had an activity. The fund is constantly included in less than 2 deals per year. Opposing the other organizations, this BB&T works on 21 percentage points more the average amount of lead investments. The usual things for fund are deals in the range of 50 - 100 millions dollars. The top amount of exits for fund were in 2013.
Related Funds
Funds with similar focus
Fund Name | Location |
Bairui Investment | China, Hangzhou, Zhejiang |
BEST Business group | - |
Bioventures Investors | Massachusetts, United States, Wellesley |
CDP Capital Technologies | - |
Citicorp Investment Bank | Central, Central Region, Singapore |
Development Capital | County Dublin, Dublin, Ireland |
Gin Lane | New York, New York, United States |
Hengjian Emerging Industries Fund | - |
Juke Capital | - |
MXC Capital | England, London, United Kingdom |
Onza Capital | Community of Madrid, Madrid, Spain |
Punchbowl | Framingham, Massachusetts, United States |
Shenzhen Lianjinshu Investment Fund | - |
Stifel Financial Corp. | Missouri, St Louis, United States |
System.One | Berlin, Germany, Kreuzberg |
Tianjin Yingxiong Jinkong Keji | China, Guangdong, Tianjin |
uBiome | California, San Francisco, United States |
Volksbank Berlin | - |
XR Trading | Chicago, Illinois, United States |
Zhangyou Rongzhi Touzi | Beijing, Beijing, China |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Enigma Technologies | $95M | 18 Sep 2018 | New York, New York, United States | ||
OvaScience | $37M | 03 Apr 2012 | Boston, Massachusetts, United States | ||
Kythera Biopharmaceuticals | $30M | 19 May 2008 | California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Enigma Technologies | $95M | 18 Sep 2018 | New York, New York, United States | ||
OvaScience | $37M | 03 Apr 2012 | Boston, Massachusetts, United States | ||
Kythera Biopharmaceuticals | $30M | 19 May 2008 | California, United States |